Form 4: Zevra Director Exercises Stock Options

Zevra Therapeutics Director John B. Bode exercised stock options, acquiring 78,400 shares of common stock.

Summary

• Director John B. Bode exercised stock options on March 24, 2026, acquiring a total of 78,400 shares of Zevra Therapeutics, Inc. common stock.
• The first transaction involved acquiring 39,200 shares at an exercise price of $4.97 per share.
• The second transaction involved acquiring an additional 39,200 shares at an exercise price of $4.89 per share.
• Following these exercises, John B. Bode directly beneficially owns 123,400 shares of ZVRA common stock.
• One option, granted on May 3, 2023, had remaining shares that will vest one day prior to the third annual meeting of the Issuer's stockholders following the grant date, subject to continued service as a director.
• The second option, granted on May 13, 2024, was fully vested at the time of exercise.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director increasing their stake through option exercise typically reflects confidence in the company's valuation and future prospects.

Positives

• Director John B. Bode's exercise of stock options and subsequent increase in direct ownership signals confidence in Zevra Therapeutics' future prospects and valuation.
• Increased insider ownership aligns the director's financial interests more closely with those of public shareholders.

Negatives

• No explicit negative information is disclosed in this Form 4 filing, which primarily reports an insider transaction.

Risks

• This Form 4 filing does not contain specific risk factor disclosures.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting schedule of one option being contingent on continued service as a director.

Industry Context

StockSavvy.ai notes that insider transactions, such as option exercises by directors, are often viewed by the market as a signal of management's confidence in the company's future performance. In the biotechnology and pharmaceutical sector, where Zevra Therapeutics operates, such signals can be particularly impactful given the long development cycles and inherent risks.

Comparison to Industry Standards

• This Form 4 filing, detailing an insider's option exercise, does not provide sufficient data for a direct comparison to industry-specific operational or financial benchmarks.

Related Party Transactions

• The transactions involve a director of Zevra Therapeutics, John B. Bode, exercising stock options granted by the company, which is a common form of related party compensation.

Stakeholder Impact

• Shareholders: The director's increased ownership through option exercise generally aligns their interests more closely with those of other shareholders.
• Employees, Customers, Suppliers, Creditors: No direct or specific impact on these stakeholder groups is mentioned or implied by this insider transaction filing.

Next Steps

• Continued service of John B. Bode as a director is required for the remaining shares of the May 3, 2023 option to vest.

Key Dates

Recommendation

While the director's option exercise signals confidence, it is a routine compensation event rather than a new investment decision at market price. It reinforces a 'hold' stance, suggesting no immediate catalyst for a 'buy' or 'sell' based solely on this transaction, but rather a confirmation of existing sentiment.

Keywords

Zevra Therapeutics, ZVRA, Stock Option Exercise, Insider Transaction, Director Ownership, Form 4, Beneficial Ownership